The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...